Literature DB >> 22595870

Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders.

Maju Mathew Koola1, Robert P McMahon, Heidi J Wehring, Fang Liu, Kristen M Mackowick, Kimberly R Warren, Stephanie Feldman, Joo-Cheol Shim, Raymond C Love, Deanna L Kelly.   

Abstract

The impact of co-morbid substance use on mortality is not well studied in psychotic disorders. The objective of this study was to examine the impact of substance use on mortality in people with psychotic disorders and alcohol and/or drug use. We examined the rate of substance use and the risk of substance use on mortality risk over a 4-10 year period in 762 people with psychotic disorders. Deceased patients were identified from the Social Security Death Index and the Maryland Division of Vital Records. Substance use was defined as regular and heavy use or abuse or dependence. Seventy seven percent had co-morbid lifetime substance use, with co-morbid cannabis and alcohol use occurring most commonly. Out of 762 subjects, 62 died during follow up. In a Cox model, predicted mortality risk was higher in age group 35-55 compared to <35 years and in males, but reduced in cannabis users. Overall five- (3.1% vs 7.5%) and ten-year mortality risk (5.5% vs. 13.6%) was lower in cannabis users than in non-users with psychotic disorders (p = 0.005) in a survival model. Alcohol use was not predictive of mortality. We observed a lower mortality risk in cannabis-using psychotic disorder patients compared to cannabis non-users despite subjects having similar symptoms and treatments. Future research is warranted to replicate these findings and to shed light on the anti-inflammatory properties of the endocannabinoid system and its role in decreased mortality in people with psychotic disorders.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22595870      PMCID: PMC3392453          DOI: 10.1016/j.jpsychires.2012.04.019

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  64 in total

1.  Medical marijuana and the law.

Authors:  Diane E Hoffmann; Ellen Weber
Journal:  N Engl J Med       Date:  2010-04-22       Impact factor: 91.245

2.  Mortality in a cohort of patients with schizophrenia: a record linkage study.

Authors:  S C Newman; R C Bland
Journal:  Can J Psychiatry       Date:  1991-05       Impact factor: 4.356

3.  Alcohol volume, drinking pattern, and cardiovascular disease morbidity and mortality: is there a U-shaped function?

Authors:  Robert P Murray; John E Connett; Suzanne L Tyas; Ruth Bond; Okechukwu Ekuma; Candice K Silversides; Gordon E Barnes
Journal:  Am J Epidemiol       Date:  2002-02-01       Impact factor: 4.897

4.  Alcohol and illicit drugs in traumatic deaths: prevalence and association with type and severity of injuries.

Authors:  Demetrios Demetriades; George Gkiokas; George C Velmahos; Carlos Brown; James Murray; Thomas Noguchi
Journal:  J Am Coll Surg       Date:  2004-11       Impact factor: 6.113

5.  Risk of selected serious cardiac events among new users of antihistamines.

Authors:  J A Staffa; J K Jones; C B Gable; J P Verspeelt; W K Amery
Journal:  Clin Ther       Date:  1995 Nov-Dec       Impact factor: 3.393

Review 6.  Assessing substance use disorder in persons with severe mental illness.

Authors:  R E Drake; S D Rosenberg; K T Mueser
Journal:  New Dir Ment Health Serv       Date:  1996

7.  Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis.

Authors:  Silvia Ortega-Gutiérrez; Eduardo Molina-Holgado; Angel Arévalo-Martín; Fernando Correa; Alma Viso; María L López-Rodríguez; Vincenzo Di Marzo; Carmen Guaza
Journal:  FASEB J       Date:  2005-06-07       Impact factor: 5.191

8.  The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells.

Authors:  Y Waksman; J M Olson; S J Carlisle; G A Cabral
Journal:  J Pharmacol Exp Ther       Date:  1999-03       Impact factor: 4.030

9.  Drug abuse in schizophrenic patients: clinical correlates and reasons for use.

Authors:  L Dixon; G Haas; P J Weiden; J Sweeney; A J Frances
Journal:  Am J Psychiatry       Date:  1991-02       Impact factor: 18.112

10.  Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study.

Authors:  Deanna L Kelly; Robert P McMahon; Fang Liu; Raymond C Love; Heidi J Wehring; Joo-Cheol Shim; Kimberly R Warren; Robert R Conley
Journal:  J Clin Psychiatry       Date:  2010-01-12       Impact factor: 4.384

View more
  10 in total

1.  Comorbidity of severe psychotic disorders with measures of substance use.

Authors:  Sarah M Hartz; Carlos N Pato; Helena Medeiros; Patricia Cavazos-Rehg; Janet L Sobell; James A Knowles; Laura J Bierut; Michele T Pato
Journal:  JAMA Psychiatry       Date:  2014-03       Impact factor: 21.596

2.  Psychoactive Substance Use by Adults With Schizophrenia Before and During Cannabis Withdrawal.

Authors:  Maju Mathew Koola; Deanna L Kelly; Robert P McMahon; Douglas L Boggs; Fang Liu; David A Gorelick
Journal:  Prim Care Companion CNS Disord       Date:  2016-09-01

3.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

4.  Relief of cannabis withdrawal symptoms and cannabis quitting strategies in people with schizophrenia.

Authors:  Maju Mathew Koola; Douglas Lee Boggs; Deanna Lynn Kelly; Fang Liu; Jared Allen Linthicum; Hailey Elaine Turner; Robert Patrick McMahon; David Alan Gorelick
Journal:  Psychiatry Res       Date:  2013-08-20       Impact factor: 3.222

Review 5.  A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis.

Authors:  Justin Davis; Harris Eyre; Felice N Jacka; Seetal Dodd; Olivia Dean; Sarah McEwen; Monojit Debnath; John McGrath; Michael Maes; Paul Amminger; Patrick D McGorry; Christos Pantelis; Michael Berk
Journal:  Neurosci Biobehav Rev       Date:  2016-04-09       Impact factor: 8.989

6.  Total and cause-specific standardized mortality ratios in patients with schizophrenia and/or substance use disorder.

Authors:  Ina H Heiberg; Bjarne K Jacobsen; Ragnar Nesvåg; Jørgen G Bramness; Ted Reichborn-Kjennerud; Øyvind Næss; Eivind Ystrom; Christina M Hultman; Anne Høye
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

7.  Differential effects of Δ9-tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model.

Authors:  Alexandre Seillier; Alex A Martinez; Andrea Giuffrida
Journal:  PLoS One       Date:  2020-03-12       Impact factor: 3.240

8.  Effect of substance use on premature mortality among severely hypertensive African Americans.

Authors:  Vinithra Varadarajan; Chidinma A Ibe; J Hunter Young
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-03-07       Impact factor: 3.738

Review 9.  Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions.

Authors:  Petter Andreas Ringen; John A Engh; Astrid B Birkenaes; Ingrid Dieset; Ole A Andreassen
Journal:  Front Psychiatry       Date:  2014-09-26       Impact factor: 4.157

Review 10.  Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis.

Authors:  Toby Pillinger; Katherine Beck; Brendon Stubbs; Oliver D Howes
Journal:  Br J Psychiatry       Date:  2017-10-05       Impact factor: 9.319

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.